P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects

Area of Science:

• Neuroscience
• Psychiatry
• Cognitive Science

Background:

• Auditory P50 suppression, a measure of sensory gating, is often impaired in chronic schizophrenia.
• This deficit suggests a loss of normal inhibitory processes in the brain.

Purpose of the Study:

• To investigate P50 suppression deficits in recent-onset schizophrenia.
• To explore the relationship between P50 suppression, clinical symptoms, and attentional impairment.
• To assess the effect of atypical (risperidone) versus typical antipsychotic medication on P50 suppression.

Main Methods:

• Event-related potential (ERP) recordings were used to measure auditory P50 suppression in 22 recent-onset schizophrenia patients and 11 healthy controls.
• Clinical symptoms, anxiety, depression, anergia, and attentional capacity were assessed.
• Patients received either risperidone or a typical antipsychotic medication.

Main Results:

• Disrupted P50 suppression was observed in patients with recent-onset schizophrenia, indicating early-stage illness involvement.
• Impaired P50 suppression correlated with higher ratings of anxiety, depression, anergia, and attentional deficits.
• Risperidone treatment led to improved P50 suppression compared to typical antipsychotic medication.

Conclusions:

• P50 suppression deficits are present early in schizophrenia and are linked to cognitive impairments and clinical symptoms.
• This neurophysiological measure may serve as an indicator of disordered neurocognition in schizophrenia.
• Atypical antipsychotics like risperidone may positively impact sensory gating mechanisms in schizophrenia.